ArticleOpen forum infectious diseases2021
Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19.
Article in Open forum infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Pooled it
- Efficacy and safety of sotrovimab in patients with COVID-19: A rapid review and meta-analysis.Reviews in medical virology · 2022Pooled it
- SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.The Cochrane database of systematic reviews · 2021Pooled it
- Within-trial economic analysis of resource use from COMET-ICE: A phase 3 clinical trial evaluating sotrovimab for the treatment of patients with COVID-19 at high risk of progression.Journal of managed care & specialty pharmacy · 2022Trial
- Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19.Frontiers in immunology · 2022Trial
- Article
- Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis.World journal of virology · 2024Article
- Effectiveness of Monoclonal Antibody Therapy for Preventing COVID-19 Hospitalization and Mortality in a Statewide Population.Rhode Island medical journal (2013) · 2023Article
- Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study.Journal of the Pediatric Infectious Diseases Society · 2023Article
- Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes.JAMA network open · 2023Article
- COVID-19 monoclonal antibody treatment impact on symptoms and post-COVID conditions among high-risk patients at a Federally Qualified Health Center.BMC infectious diseases · 2023Article
- Are monoclonal antibodies effective in patients with severe obesity in SARS-CoV-2 infected?Immunity, inflammation and disease · 2023Article
- A multimodal strategy to improve race/ethnic group equity in administration of neutralizing monoclonal antibody treatment for COVID-19 outpatients.Journal of clinical and translational science · 2023Article
- A beacon in the dark: COVID-19 course in CVID patients from two European countries: Different approaches, similar outcomes.Frontiers in immunology · 2023Article
- Using a web platform for equitable distribution of COVID-19 monoclonal antibodies: a case study in resource allocation.Frontiers in public health · 2023Article
- Article
- Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19.Infectious diseases and therapy · 2022Article
- Functionality of Monoclonal Antibody Therapy in SARS-CoV-2.Journal of medical cases · 2022Article
- Real-world evaluation of the impact of two anti-SARS-CoV-2 monoclonal antibody regimens on COVID-19 hospitalizations in older adults.Journal of medical virology · 2022Article
- Evaluation of Monoclonal Antibodies in Preventing Hospitalizations, Emergency Department Visits, and Mortality in High-Risk COVID-19 Patients.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundNeutralizing monoclonal antibodies (MAbs) are a promising therapy for early coronavirus disease 2019 (COVID-19), but their effectiveness has not been confirmed in a real-world setting.
methodsIn this quasi-experimental pre-/postimplementation study, we estimated the effectiveness of MAb treatment within 7 days of symptom onset in high-risk ambulatory adults with COVID-19. The primary outcome was a composite of emergency department visits or hospitalizations within 14 days of positive test. Secondary outcomes included adverse events and 14-day mortality. The average treatment effect in the treated for MAb therapy was estimated using inverse probability of treatment weighting and the impact of MAb implementation using propensity-weighted interrupted time series analysis.
resultsPre-implementation (July-November 2020), 7404 qualifying patients were identified. Postimplementation (December 2020-January 2021), 594 patients received MAb treatment and 5536 did not. The primary outcome occurred in 75 (12.6%) MAb recipients, 1018 (18.4%) contemporaneous controls, and 1525 (20.6%) historical controls. MAb treatment was associated with decreased likelihood of emergency care or hospitalization (odds ratio, 0.69; 95% CI, 0.60-0.79). After implementation, the weighted probability that a given patient would require an emergency department visit or hospitalization decreased significantly (0.7% per day; 95% CI, 0.03%-0.10%). Mortality was 0.2% (n = 1) in the MAb group compared with 1.0% (n = 71) and 1.0% (n = 57) in pre- and postimplementation controls, respectively. Adverse events occurred in 7 (1.2%); 2 (0.3%) were considered serious.
conclusionsMAb treatment of high-risk ambulatory patients with early COVID-19 was well tolerated and likely effective at preventing the need for subsequent emergency department or hospital care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.